Contract

Temp – Scientist

Analytical Chemistry, Research

Updated on 7/12/2025

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Develops treatments for neurological disorders

No salary listed

Junior, Mid

Company Does Not Provide H1B Sponsorship

San Diego, CA, USA

In Person

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Bachelor's degree in Chemistry, Biochemistry or similar discipline and 2+ years of experience in pharmaceutical industry, specifically small molecule purification and analysis.
  • Hands-on experiences with HPLC / SFC Chromatography and liquid robotics preferred.
  • Experience with analytical method development and preparative chromatography for small molecule chiral and achiral pharmaceutical compounds.
  • Experience in instrument maintenance and troubleshooting preferred OR MS degree in Chemistry, Biochemistry or similar discipline and some industry experience as noted above OR PhD degree in Chemistry, Biochemistry or similar discipline and some industry or relevant experience a plus.
  • Ability to identify complex problems and solves routine problems.
  • Ability to work under various timelines, while maintaining quality of work.
  • Working knowledge of HPLC/SFC chromatography. Analytical and preparative focus with this technology is required.
  • Continuous drive to increase lab productivity and throughput through scientific creativity.
  • Recognizes fundamental anomalies in data points and identifies issues in experiments / processes.
  • Begins to understand how to think outside of the technical process and consider the impact decisions will have on the broader scientific goals.
  • Strong knowledge of one scientific discipline.
  • Good knowledge of scientific principles, methods and techniques.
  • Good knowledge and demonstrated ability working with a variety of laboratory equipment/tools.
  • Ability to work as part of a team Strong computer skills.
  • Good problem-solving, analytical thinking skills.
  • Detail oriented.
  • Ability to meet deadlines.
  • Good project management skills.
  • Strong communication skills, ability to work independently, and creative approaches to problem solve, are essential in performing daily tasks and responsibilities.
Responsibilities
  • Performs daily HPLC achiral small molecule purification and analysis.
  • Executes and/or optimizes HPLC/SFC methods for achiral/chiral small molecules; supports the development of chiral and achiral methodologies to purify small molecules using mass-directed HPLC and SFC technology.
  • Perform routine instrument maintenance, repair and may troubleshoot complex instrument issues.
  • Operates liquid handling robotics.
  • Uses sample data to develop preliminary analysis and findings.
  • Support the development of presentations of laboratory studies/analysis and findings.
  • Regularly sets up laboratory for new and/or continued purification and analysis.
  • Other duties as assigned.
Desired Qualifications
  • Hands-on experiences with HPLC / SFC Chromatography and liquid robotics preferred.
  • Experience in instrument maintenance and troubleshooting preferred.
Neurocrine Biosciences

Neurocrine Biosciences

View

Neurocrine Biosciences develops treatments for neurological and endocrine diseases. Their main product, INGREZZA® (valbenazine), is used to treat tardive dyskinesia in adults. The company also has several other drug candidates in clinical trials for conditions like Parkinson's disease and endometriosis. Unlike many competitors, Neurocrine focuses specifically on these areas, allowing them to build a specialized portfolio. Their goal is to improve the lives of patients with these disorders through effective treatments.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA fast-track designation could expedite Neurocrine's drug approvals.
  • Growing mental health awareness expands market for Neurocrine's neuropsychiatric treatments.
  • Collaborations with academic institutions enhance Neurocrine's research and innovation access.

What critics are saying

  • Increased competition from Teva's generic Austedo affects INGREZZA's market share.
  • Patent litigation may delay NBI-1117568's commercialization for schizophrenia.
  • Strategic shifts from new CIO could disrupt Neurocrine's IT operations.

What makes Neurocrine Biosciences unique

  • Neurocrine focuses on neurological and endocrine disorders, a niche in biopharmaceuticals.
  • INGREZZA® is a leading treatment for tardive dyskinesia, setting Neurocrine apart.
  • Neurocrine's pipeline includes innovative drugs like NBI-1117568 for schizophrenia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

Company News

Cache Valley Daily
Jun 9th, 2025
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

SAN DIEGO, June 9, 2025 /PRNewswire/ - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025.

GlobeNewswire
Jun 2nd, 2025
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568

Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine...

PR Newswire
May 15th, 2025
Neurocrine Biosciences Presents Data On Improvements In Physiologic Glucocorticoid Dosing And Select Reproductive Hormones In Patients With Classic Congenital Adrenal Hyperplasia Taking Crenessity™ (Crinecerfont)

90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid Reduction. Observed Rates of Select Reproductive Hormone Normalization in Adult Males Taking CRENESSITY with Substantial Glucocorticoid Dose Reductions. Findings Presented at the 2025 American Association of Clinical Endocrinology Annual MeetingSAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont). The data showed that a substantial proportion of pediatric patients with classic congenital adrenal hyperplasia achieved physiologic-range glucocorticoid doses and normal androstenedione levels. Additionally, adult male patients with classic congenital adrenal hyperplasia observed improvements in select reproductive hormone levels. Both adult and pediatric patients achieved substantial reductions in glucocorticoid doses. These results were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting in Orlando

PR Newswire
May 14th, 2025
Neurocrine Biosciences Presents Findings Contributing To The Growing Body Of Evidence On The Impact Of High-Dose Glucocorticoids On Clinical Outcomes In Congenital Adrenal Hyperplasia

Most Studies Meeting the Literature Review Criteria Found That a Higher Glucocorticoid Dose was Statistically Significantly Associated with Adverse Clinical OutcomesFindings Presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research Annual MeetingSAN DIEGO, May 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented today a systematic literature review illustrating the relationship between higher glucocorticoid dose and adverse clinical outcomes, including decreased bone mineral density, increased insulin resistance and higher body mass index, in patients with congenital adrenal hyperplasia. This study was presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting in Montreal, Canada.Congenital adrenal hyperplasia (CAH) is a rare, lifelong genetic condition linked to overproduction of adrenal androgens and cortisol deficiency. CAH is traditionally treated with lifelong high-dose glucocorticoids (GCs), which increase the risk of complications across multiple aspects of health. However, the relationship between GC dose and adverse clinical outcomes in CAH has not been fully explored. This systematic literature review was conducted to analyze the relationship between GC dose and clinical outcomes, and is the first to capture the impact of higher GC dose on the incidence and severity of all relevant adverse clinical outcomes in patients with CAH."CAH requires lifelong glucocorticoid therapy to manage adrenal androgen excess and cortisol deficiency, but high doses often lead to significant complications, including cardiometabolic, bone and growth issues," said Eiry W

Clinical Trial Vanguard
May 1st, 2025
Neurocrine Starts Phase 3 Trial of NBI-1117568 for Schizophrenia

Nxera Pharma's partner, Neurocrine Biosciences, has launched a Phase 3 trial for NBI-1117568, an oral M4 selective receptor agonist, for schizophrenia treatment.